Home » Topics » Endocrine/metabolic, BioWorld Science

Endocrine/metabolic, BioWorld Science
RSS

Roussel Uclaf discloses integrin antagonists for bone disorders

Nov. 26, 1997

ProLease hGH slated to enter phase III

Nov. 26, 1997

Sertoli and Carolinas Medical Center collaborate to develop novel diabetes therapy

Nov. 26, 1997

FDA approves sibutramine for the treatment of obesity

Nov. 25, 1997

Bayer introduces statin in Germany

Nov. 25, 1997

Novel beta-agonists for obesity and diabetes described by SmithKline Beecham

Nov. 25, 1997

Dainippon's aldose reductase inhibitor in preclinical testing

Nov. 25, 1997

Novartis launches once-monthly formulation of Sandostatin

Nov. 24, 1997

Role of substance P in PTH secretion described

Nov. 24, 1997

GH secretagogues under development at Merck & Co.

Nov. 24, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...